New late-stage trial data show Regeneron and Roche's antibody cocktail against Covid-19 cut hospitalisation or death by 70 percent versus placebo in non-hospitalised patients, the Swiss drugmaker said on Tuesday.

The shot, consisting of casirivimab and imdevimab antibodies developed by Regeneron with financial help from the US government, also met all key secondary endpoints in the phase III trial with 4,567 participants, including reducing symptom duration to 10 days from 14, Roche said...